The invention includes isolated nucleic acid molecules encoding a Rhesus ob gene product that regulates obesity in mammals. A preferred embodiment consisting of a native DNA sequence is disclosed, as are vectors and methods for expressing the Rhesus ob gene product.
Margret B. Basinski - Indianapolis IN Richard D. DiMarchi - Carmel IN David B. Flora - Greenfield IN William F. Heath - Fishers IN James A. Hoffmann - Greenwood IN Brigitte E. Schoner - Monrovia IN James E. Shields - Noblesville IN David L. Smiley - Greenfield IN
Assignee:
Eli Lilly and Company - Indianapolis IN
International Classification:
A61K 3800
US Classification:
514 12
Abstract:
The present invention provides anti-obesity proteins, which when administered to a patient regulate fat tissue. Accordingly, such agents allow patients to overcome their obesity handicap and live normal lives with much reduced risk for type II diabetes, cardiovascular disease and cancer.
Margret B. Basinski - Indianapolis IN Richard D. DiMarchi - Carmel IN William F. Heath - Fishers IN Brigitte E. Schoner - Monrovia IN
Assignee:
Eli Lilly and Company - Indianapolis IN
International Classification:
A61K 3800 C07K 710 C07K 700
US Classification:
530324
Abstract:
The present invention provides anti-obesity proteins, which when administered to a patient regulate fat tissue. Accordingly, such agents allow patients to overcome their obesity handicap and live normal lives with much reduced risk for type II diabetes, cardiovascular disease and cancer.
Margret B. Basinski - Indianapolis IN Richard D. DiMarchi - Carmel IN William F. Heath - Fishers IN Brigitte E. Schoner - Monrovia IN
Assignee:
Eli Lilly and Company - Indianapolis IN
International Classification:
A61K 3800 C07K 700 C07K 710
US Classification:
530324
Abstract:
The present invention provides anti-obesity proteins, which when administered to a patient regulate fat tissue. Accordingly, such agents allow patients to overcome their obesity handicap and live normal lives with much reduced risk for type II diabetes, cardiovascular disease and cancer.
Margret B. Basinski - Indianapolis IN Richard D. DiMarchi - Carmel IN David B. Flora - Greenfield IN William F. Heath - Fishers IN James A. Hoffmann - Greenwood IN Brigitte E. Schoner - Monrovia IN James E. Shields - Noblesville IN David L. Smiley - Greenfield IN
Assignee:
Eli Lilly and Company - Indianapolis IN
International Classification:
A61K 3800 C07K 100 C07K 700 C07K 500
US Classification:
514 12
Abstract:
The present invention provides anti-obesity proteins, which when administered to a patient regulate fat tissue. Accordingly, such agents allow patients to overcome their obesity handicap and live normal lives with much reduced risk for type II diabetes, cardiovascular disease and cancer.
Margret Basinski - Indianapolis IN Richard D. DiMarchi - Carmel IN David B. Flora - Greenfield IN William F. Heath - Fishers IN James A. Hoffmann - Greenwood IN Brigitte E. Schoner - Monrovia IN James E. Shields - Noblesville IN David L. Smiley - Greenfield IN
Assignee:
Eli Lilly and Company - Indianapolis IN
International Classification:
A61K 3800 C07K 710
US Classification:
530324
Abstract:
The present invention provides anti-obesity proteins, which when administered to a patient regulate fat tissue. Accordingly, such agents allow patients to overcome their obesity handicap and live normal lives with much reduced risk for type II diabetes, cardiovascular disease and cancer.
Margret B. Basinski - Indianapolis IN Richard D. DiMarchi - Carmel IN David B. Flora - Greenfield IN William F. Heath - Fishers IN James A. Hoffmann - Greenwood IN Brigitte E. Schoner - Monrovia IN James E. Shields - Noblesville IN David L. Smiley - Greenfield IN
Assignee:
Eli Lilly and Company - Indianapolis IN
International Classification:
A61K 3800 C07K 1400
US Classification:
530324
Abstract:
The present invention provides anti-obesity proteins, which when administered to a patient regulate fat tissue. Accordingly, such agents allow patients to overcome their obesity handicap and live normal lives with much reduced risk for type II diabetes, cardiovascular disease and cancer.
Margret B. Basinski - Indianapolis IN Richard D. DiMarchi - Carmel IN David B. Flora - Greenfield IN William F. Heath - Fishers IN James A. Hoffmann - Greenwood IN Brigitte E. Schoner - Monrovia IN James E. Shields - Noblesville IN David L. Smiley - Greenfield IN
Assignee:
Eli Lilly and Company - Indianapolis IN
International Classification:
A61K 3800 C07K 710 C07K 700
US Classification:
530324
Abstract:
The present invention provides anti-obesity proteins, which when administered to a patient regulate fat tissue. Accordingly, such agents allow patients to overcome their obesity handicap and live normal lives with much reduced risk for type II diabetes, cardiovascular disease and cancer.